Sudobio is a biotechnology company focused on developing next-generation protein degradation therapeutics for the treatment of diseases with high unmet medical needs.

Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Our lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.

Frazier Life Sciences

Velosity Capital

Sanofi Ventures

50 South Capital

Monograph Capital

Enavate Sciences

Eventide

Surveyor Capital

Sudo Biosciences

Sudo Biosciences lands additional $30m for TYK2 inhibitors with potential in Alzheimer’s

Dementia Discovery Fund (DDF) joins new investors, citing Sudo’s potential in multiple neuroinflammatory diseases, including Alzheimer’s.

#longevity #investment #Alzheimers

Improving care for patients living with debilitating neuroinflammatory and autoimmune conditions. 💊🌟 
We're thrilled to announce our investment in Sudo Biosciences. The company is developing best-in-class precision TYK2 inhibitors, potential game-changers in treating immune-mediated #inflammatory conditions and #neurodegenerative diseases. 

This investment will support Sudo Biosciences in advancing two precision TYK2 inhibitors into the clinic for neuroinflammatory and autoimmune conditions including #multiplesclerosis, #ALS, and #psoriasis.
Read more: https://bwnews.pr/498nmea

Excited to announce we have completed a second close of its Series B financing, raising an additional $30 million from new investors Dementia Discovery Fund (DDF)  (DDF, a SV Health Investors Fund), Leaps by Bayer, and UPMC Enterprises the innovation, commercialization and venture capital arm of UPMC. This brings the total raised in this upsized round to $147 million.

“We are pleased to welcome these new investors as they each offer unique strategic value which will be meaningful for Sudo as we advance our precision TYK2 inhibitors into the clinic,” said Scott Byrd, Chief Executive Officer, Sudo Biosciences. “This further funding enhances our ability to optimize the development of our pipeline programs.”

Read the release:

https://lnkd.in/ed_5677K

We had an excellent crowd on hand to hear our very own Mike Bolinder, Scott Byrd, CEO of Sudo Biosciences, and Derek A Small, founder of Luson Bioventures, speaking at the #JP2024 in San Francisco. 

Special thanks to the Indiana Economic Development Corporation, Elevate Ventures, and Barnes & Thornburg LLP for partnering with BioCrossroads and giving us this incredible opportunity to showcase Indiana as a #lifesciences powerhouse.  

Thanks Nasdaq for celebrating our recent $116M Series B funding round in Times Square today! 

Exciting start to kick off 2024, and looking forward to seeing everyone at #JPM24 next week. 

Sharing our Series B press release: 

https://lnkd.in/edgkg4dg 

#TYK2 #biotech #funding 

COM:SUDOBIO

Sudobio

Analysis Not Available